Plexium is a next-generation targeted protein degradation (TPD) company, leading the way in the rational design and discovery of monovalent protein degraders across a wide range of modalities. Plexium has built a comprehensive best-in-class TPD platform, powered by a proprietary high-throughput cell-based screening (uHTS) technology. Plexium’s next-generation TPD programs extend beyond the limited applications of Proteolysis Targeting Chimeras (PROTACs) and cereblon imids, unravelling the boundless possibilities of true drug-like protein degraders.
Plexium Inc. announced the appointment of experienced biopharmaceutical leader Percival Barretto-Ko as President and Chief Executive Officer and a member of the Board of Directors
2021/01/21Plexium Announces $35m Financing to Advance Pipeline of Novel Protein Degraders
Funds will help advance Plexium’s DELPhe platform to discover novel E3 ligase-modulating therapeutics to treat cancer and neurodegenerative diseases
